Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders

Míreanna comhchosúla

• Leukemic blasts in transformed JAK2-V617F–positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.
  de réir: Alexandre Theocharides, et al.
  Foilsithe / Cruthaithe: (2007)
• Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
  de réir: Róbert Královics, et al.
  Foilsithe / Cruthaithe: (2005)
• A Gain-of-Function Mutation of<i>JAK2</i>in Myeloproliferative Disorders
  de réir: Róbert Královics, et al.
  Foilsithe / Cruthaithe: (2005)
• Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
  de réir: Daniela Pietra, et al.
  Foilsithe / Cruthaithe: (2007)
• Angiogenesis and vascular endothelial growth factor‐/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and <i>JAK2‐V617F</i> mutational status
  de réir: Michael Medinger, et al.
  Foilsithe / Cruthaithe: (2009)